Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis reports positive data from Tasigna comparison trial

Novartis reports positive data from Tasigna comparison trial

7th June 2010

Novartis has presented new data which highlights the effectiveness of its leukaemia treatment Tasigna compared to the alternative drug Glivec (imatinib).

According to data from the phase III study, Novartis’ new drug demonstrated superior performance in key measures of treatment efficacy when used among adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia.

It was shown to provide deeper levels of molecular response than imatinib and significantly reduced progression to accelerated phase and blast crisis, while three times as many patients achieved undetectable disease at the molecular level using Tasigna.

Dr Richard Larson, a study investigator, said this demonstrated the advantages Tasigna can offer compared to the current gold standard treatment.

He added: “The efficacy and safety findings achieved by Tasigna in this study provide patients and physicians with an important new treatment option.”

This comes after Novartis published new trial data demonstrating the efficacy of its pancreatic neuroendocrine tumour Afinitor last week.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.